NHS to launch subscription service to encourage R&D
11 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
List view / Grid view
NHS England
Cell therapy rejected for aggressive adult lymphoma on the NHS
24 September 2018 | By Iqra Farooq (European Pharmaceutical Review)
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS...
NHS England partners with Merck allowing people with MS immediate access to cladribine
9 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
NHS England has announced a commercial agreement that allows patients in England immediate access to the innovative new multiple sclerosis treatment...
NICE approves three quarters of drugs from the Cancer Drugs Fund
14 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
Kadcyla new deal means NICE positive recommendation in draft guidance
22 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
14 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
NHS England to fund bionic eye surgery
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in RP...
What is a biosimilar medicine? NHS England explains all in new publication
25 September 2015 | By Victoria White
The British Generic Manufacturers Association, the Association of the British Pharmaceutical Industry (ABPI), and the UK BioIndustry Association (BIA) have joined forces to welcome NHS England’s new publication “What is a biosimilar medicine?”.